MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Annals of Advanced Biomedical Sciences
ISSN: 2641-9459

Harnessing Molecular Glues for Next-Generation Vaccine, Cancer and Cardiovascular Disease Drug Development: A Comprehensive Review

Chava SR[1], Liu JL[1,2] and Bashir S[1,2]*

[1]Department of Chemistry, Texas A&A University -Kingsville, USA
[2]Texas A&M Energy Institute, College Station, USA

***Corresponding author:** Sajid Bashir, Texas A&M University, Energy Institute, College Station, Texas, USA; Email: Br9@tamuk.edu

Review Article
Volume 8 Issue 1
Received Date: January 07, 2025
Published Date: March 11, 2025
DOI: 10.23880/aabsc-16000235

Abstract

The COVID-19 pandemic has underscored the critical need for innovative vaccine technologies and therapeutics. Molecular glues small molecules that facilitate protein-protein interactions have garnered significant interest for their potential applications in vaccine formulation, cancer drug development, and cardiovascular disease treatments. This comprehensive review explores the diverse landscape of vaccine technologies, rangi ng from mRNA and protein subunit vaccines to viral vector and nucleic acid-based vaccines, and elucidates how molecular glues can enhance their efficacy. Furthermore, it delves into the burgeoning fields of cancer drug development and cardiovascular disease therapies, highlighting the role of molecular glues in targeting protein-protein interactions implicated in these diseases. By examining the molecular mechanisms, recent advancements, and future prospects of molecular glue-based approaches, this review provides a thorough understanding of their transformative potential in combating infectious diseases, cancer, and cardiovascular ailments.

Keywords: COVID-19; Health; Molecular Glues

Abbreviations

CVDs: Cardiovascular Diseases; PPIs: Protein-Protein Interactions; LNPs: Lipid Nanoparticles; IMiDs: Immunomodulatory Drugs; PCSK9: Proprotein Convertase Subtilisin/Kexin Type 9; LDL: Low-Density Lipoprotein.

Introduction

The rapid spread of the COVID-19 pandemic has spurred unprecedented global efforts to develop vaccines and therapeutics to mitigate its impact. This viral outbreak not only highlighted the urgency of addressing emergent infectious diseases but also underscored the limitations of existing vaccine platforms. Traditional vaccine technologies, while effective, face significant challenges such as prolonged development timelines, difficulties in large-scale manufacturing, and limited adaptability to rapidly evolving viral variants. Moreover, the logistical complexities associated with the distribution and administration of these vaccines, particularly in low-resource settings, has further emphasized the need for more versatile and resilient vaccine development strategies.

Simultaneously, cancer and cardiovascular diseases continue to impose a substantial burden on global public health systems. Cancer remains one of the leading causes of mortality worldwide, with millions of new cases diagnosed each year. The intricate nature of cancer, characterized by genetic heterogeneity and the ability of tumor cells to develop resistance to conventional therapies, necessitates innovative approaches for effective treatment. Traditional cancer therapies, including surgery, radiation, and chemotherapy, often lack specificity, leading to significant side effects and diminishing quality of life for patients. While targeted therapies and immunotherapies have made substantial strides in improving outcomes, the quest for more precise and adaptable treatment modalities persists.

Cardiovascular diseases (CVDs), encompassing conditions such as heart failure, atherosclerosis, and hypertension, remain the leading cause of death globally. The pathophysiology of CVDs involves complex molecular and cellular mechanisms, including dysregulated protein-protein interactions (PPIs) that govern critical processes like cardiac contractility, vascular tone regulation, and lipid metabolism. Despite advances in medical treatments and preventive strategies, the prevalence of CVDs continues to rise, driven by factors such as aging populations, lifestyle changes, and the increasing incidence of comorbidities like diabetes and obesity.

At the intersection of these pressing health challenges lies the emerging field of molecular glues small molecules that facilitate or stabilize specific PPIs. Unlike traditional small molecule inhibitors, which typically bind to a single protein target to block its function, molecular glues act as mediators that bring together two or more proteins, thereby modulating their interactions in a controlled manner. This unique mechanism of action allows molecular glues to target "undruggable" proteins that lack conventional binding sites, expanding the scope of therapeutic targets beyond what was previously feasible with existing drug modalities.

The significance of molecular glues extends across various domains of medicine, offering transformative potential in vaccine development, cancer therapy, and cardiovascular disease management. In the realm of vaccines, molecular glues can enhance the stability and delivery of vaccine components, improve antigen presentation, and modulate immune signaling pathways to elicit more robust and durable immune responses. For instance, in mRNA vaccine platforms, which have gained prominence due to their rapid development and high efficacy against COVID-19, molecular glues can stabilize lipid nanoparticles (LNPs) that encapsulate mRNA, thereby enhancing their stability and delivery efficiency. This stabilization is crucial for maintaining the integrity of mRNA molecules, preventing their degradation, and ensuring optimal antigen expression levels, which are essential for eliciting a strong immune response.

In cancer drug development, molecular glues offer a novel approach to target PPIs that are pivotal for tumor growth, survival, and metastasis. Traditional targeted therapies often face limitations related to specificity and the development of drug resistance. Molecular glues, by inducing or stabilizing specific PPIs, can lead to the selective degradation of oncogenic proteins or the disruption of critical signaling pathways within cancer cells. For example, immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide act as molecular glues by binding to cereblon (CRBN), a component of the E3 ubiquitin ligase complex, thereby recruiting and degrading transcription factors essential for multiple myeloma cell survival. This targeted protein degradation not only disrupts vital survival pathways in cancer cells but also minimizes adverse effects on normal cells, enhancing the therapeutic index and patient tolerability.

Cardiovascular disease therapy also stands to benefit significantly from the application of molecular glues. PPIs play a crucial role in regulating numerous aspects of cardiovascular function, including cardiac contractility, vascular smooth muscle tone, and lipid metabolism. Dysregulation of these interactions can lead to pathological conditions such as heart failure, hypertension, and atherosclerosis. Molecular glues can modulate these interactions with high specificity, offering precise therapeutic interventions. For instance, molecular glues targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) can enhance its degradation, leading to increased levels of low-density lipoprotein (LDL) receptors and reduced LDL cholesterol levels, thereby mitigating the risk of atherosclerosis and associated cardiovascular events. Additionally, by stabilizing interactions involved in calcium signaling pathways, molecular glues can improve cardiac contractility and rhythm, offering potential treatments for heart failure and arrhythmias.

The versatility of molecular glues extends beyond these primary applications, offering potential benefits in the development of therapeutics for autoimmune disorders, neurodegenerative diseases, and other complex conditions where PPIs are dysregulated. The ability to precisely modulate PPIs opens new avenues for designing highly specific and effective treatments that can be tailored to individual patient profiles, aligning with the principles of precision medicine. Advances in high-throughput screening, computational modeling, and structural biology have accelerated the discovery and optimization of molecular glues, enabling the identification of compounds with desirable pharmacokinetic and pharmacodynamic properties.

Despite the promising potential of molecular glues, several challenges remain in their development and clinical application. Achieving the necessary specificity and selectivity to minimize off-target effects is paramount to ensuring safety and efficacy. Additionally, understanding the pharmacokinetics and pharmacodynamics of these molecules is essential for optimizing their therapeutic use. The stability, solubility, and bioavailability of molecular glues must be thoroughly evaluated to ensure their effectiveness in vivo. Furthermore, the complex nature of PPIs and the dynamic interplay between proteins necessitate a deep understanding of the underlying biology to design effective molecular glues.

Future research in the field of molecular glues is poised to address these challenges through the integration of innovative screening methods, advanced computational techniques, and a thorough exploration of the mechanistic underpinnings of PPIs. The continued development of next-generation molecular glues with enhanced specificity, broader target ranges, and improved drug-like properties will further expand their applicability and therapeutic efficacy. As the understanding of PPIs and their role in disease pathology deepens, molecular glues are likely to become integral components of the therapeutic arsenal, offering solutions to some of the most intractable health challenges of our time.

By examining the molecular mechanisms, recent advancements, and future prospects of molecular glue-based approaches, this review provides a thorough understanding of their transformative potential in combating infectious diseases, cancer, and cardiovascular ailments.

Vaccine Technologies: A Multifaceted Approach

The evolution of biomedical science has continuously sought innovative strategies to combat emerging and persistent health challenges, with infectious diseases, cancer, and cardiovascular disorders standing out as critical areas necessitating advanced therapeutic interventions. The COVID-19 pandemic, in particular, underscored the urgent need for rapid, adaptable, and effective solutions to emergent infectious threats, revealing both the potential and limitations of existing vaccine platforms. Traditional vaccine technologies, while effective, often grapple with prolonged development timelines, scalability issues, and limited adaptability to rapidly evolving viral variants. Additionally, the logistical complexities associated with the distribution and administration of these vaccines, especially in low-resource settings, has highlighted the necessity for more versatile and resilient vaccine development strategies. Concurrently, cancer remains one of the leading causes of mortality worldwide, characterized by its genetic heterogeneity and the ability of tumor cells to develop resistance to conventional therapies. Traditional cancer treatments, including surgery, radiation, and chemotherapy, often lack the specificity required to eliminate cancer cells without causing significant collateral damage to healthy tissues, thereby diminishing the quality of life for patients. Although targeted therapies and immunotherapies have made substantial strides in improving outcomes, the quest for more precise and adaptable treatment modalities persists. Similarly, cardiovascular diseases (CVDs), encompassing conditions such as heart failure, atherosclerosis, and hypertension, continue to impose a substantial burden on global public health systems, with their pathogenesis involving complex molecular mechanisms, including dysregulated protein-protein interactions (PPIs) that govern critical processes like cardiac contractility, vascular tone regulation, and lipid metabolism. Despite advances in medical treatments and preventive strategies, the prevalence of CVDs continues to rise, driven by factors such as aging populations, lifestyle changes, and the increasing incidence of comorbidities like diabetes and obesity.

At the intersection of these pressing health challenges lies the emerging field of molecular glues a novel class of small molecules designed to precisely modulate PPIs. Unlike traditional small molecule inhibitors that typically target a single protein to inhibit its function, molecular glues act as bridges, bringing together two or more proteins to facilitate or stabilize their interactions in a controlled manner. This unique mechanism allows for the selective degradation of disease-associated proteins or the stabilization of beneficial protein complexes, thereby offering a versatile approach to targeting previously inaccessible proteins. By inducing proximity-dependent effects such as ubiquitination and subsequent proteasomal degradation, molecular glues can effectively dismantle pathological protein networks or enhance protective ones, providing a powerful tool in the therapeutic arsenal. The significance of molecular glues is particularly evident in their ability to overcome the "undruggable" nature of many critical proteins involved in disease progression. This broadens the scope of therapeutic targets beyond what was previously feasible with existing drug modalities, enabling interventions that are both highly specific and efficacious. Moreover, molecular glues offer several advantages over traditional therapeutics, including a broader target scope, enhanced specificity, and a catalytic mode of action where a single molecule can induce multiple degradation events, thereby enhancing potency and reducing required dosages. Their versatility extends across various disease applications, from oncology to autoimmune disorders, neurodegenerative diseases, and infectious diseases, by modulating relevant PPIs with high precision.

In the realm of vaccine development, the advent of molecular glues holds significant promise in addressing key challenges related to antigen stability, efficient delivery, and robust immune stimulation. For instance, in mRNA vaccines, molecular glues can stabilize lipid nanoparticles (LNPs) that encapsulate mRNA, thereby enhancing their stability and delivery efficiency. This stabilization is crucial for maintaining the integrity of mRNA molecules, preventing their degradation, and ensuring optimal antigen expression levels, which are essential for eliciting a strong immune response. Additionally, in protein subunit vaccines, molecular glues can maintain the native conformation of viral proteins, enhancing their immunogenicity and ensuring a more effective immune response. This capability not only improves the efficacy of existing vaccine platforms but also facilitates the rapid adaptation of vaccines to emerging viral variants, thereby enhancing global health security.

In cancer therapy, molecular glues offer a transformative approach by enabling the selective degradation of oncogenic proteins that drive tumor growth and survival. Immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide function as molecular glues by binding to cereblon (CRBN), a component of the E3 ubiquitin ligase complex, thereby recruiting and degrading transcription factors essential for multiple myeloma cell survival. This targeted degradation disrupts critical survival pathways in cancer cells while minimizing adverse effects on normal cells, thereby enhancing therapeutic efficacy and patient tolerability. Furthermore, the development of Proteolysis Targeting Chimeras (PROTACs) has expanded the scope of molecular glues in cancer treatment. PROTACs are bifunctional molecules that simultaneously bind to a target protein and an E3 ubiquitin ligase, effectively tagging the target protein for degradation by the proteasome. This strategy allows for the clearance of proteins previously deemed undruggable, such as transcription factors and scaffolding proteins, opening new avenues for cancer treatment and overcoming the limitations of traditional targeted therapies.

In the context of cardiovascular disease therapy, molecular glues provide a novel strategy to precisely modulate PPIs involved in critical aspects of cardiovascular function. For example, molecular glues targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) can enhance its degradation, leading to increased levels of low-density lipoprotein (LDL) receptors and reduced LDL cholesterol levels, thereby mitigating the risk of atherosclerosis and associated cardiovascular events. Additionally, molecular glues that stabilize interactions involved in calcium signaling pathways can improve cardiac contractility and rhythm, offering potential treatments for heart failure and arrhythmias. By targeting specific proteins involved in lipid metabolism and calcium homeostasis, molecular glues can provide more targeted and effective interventions for a variety of cardiovascular conditions, addressing the intricate molecular underpinnings that drive these diseases.

The integration of molecular glues into precision medicine frameworks further amplifies their therapeutic potential by enabling highly personalized interventions tailored to an individual's genetic, molecular, and clinical profiles. Precision medicine aims to deliver treatments that align with the unique molecular landscape of each patient's condition, thereby maximizing therapeutic efficacy while minimizing adverse effects. Advances in high-throughput screening, computational modeling, and structural biology have been instrumental in identifying and optimizing molecular glues with desirable pharmacokinetic and pharmacodynamic properties, facilitating the development of highly selective and potent therapeutic agents. This alignment with precision medicine principles ensures that treatments are not only effective but also bespoke to the patient's specific disease context, enhancing overall patient outcomes and advancing the frontiers of personalized healthcare.

Despite their immense potential, several challenges must be addressed to fully realize the therapeutic benefits of molecular glues. Achieving the necessary specificity and selectivity to minimize off-target effects is paramount to ensuring safety and efficacy. Additionally, understanding the pharmacokinetics and pharmacodynamics of these molecules is essential for optimizing their therapeutic use. The stability, solubility, and bioavailability of molecular glues must be thoroughly evaluated to ensure their effectiveness in vivo. Moreover, the complex nature of PPIs and the dynamic interplay between proteins necessitate a deep understanding of the underlying biology to design effective molecular glues.

Future research in the field of molecular glues is poised to address these challenges through the integration of innovative screening methods, advanced computational techniques, and a thorough exploration of the mechanistic underpinnings of PPIs. The continued development of next-generation molecular glues with enhanced specificity, broader target ranges, and improved drug-like properties will further expand their applicability and therapeutic efficacy. As the understanding of PPIs and their role in disease pathology deepens, molecular glues are likely to become integral components of the therapeutic arsenal, offering solutions to some of the most intractable health challenges of our time.

By harnessing the power of PPIs, molecular glues enable the precise modulation of critical biological processes, paving the way for more effective and personalized treatments. As research continues to advance our understanding of molecular glues and their mechanisms of action, their integration into various domains of medicine is poised to revolutionize the landscape of therapeutic interventions, addressing some of the most pressing health challenges of our time.

mRNA Vaccines

mRNA vaccines represent a groundbreaking technology that harnesses the body's cellular machinery to produce viral antigens, eliciting an immune response from Anderson EJ, et al. [1] and Polack FP, et al. [2]. Despite their rapid development and high efficacy demonstrated in combating COVID-19, mRNA vaccines face challenges related to stability, immunogenicity, and scalability. Molecular glues offer solutions by stabilizing lipid nanoparticles (LNPs) that encapsulate mRNA, thereby enhancing their stability and delivery efficiency. Additionally, molecular glues can stabilize mRNA molecules themselves, preventing degradation and optimizing antigen expression levels by Wrapp D, et al. [3] and Walls AC, et al. [4].

Protein Subunit Vaccines

Protein subunit vaccines utilize isolated viral proteins to stimulate immune responses. However, the inherent instability of isolated proteins poses challenges for vaccine formulation. Molecular glues play a pivotal role in stabilizing these proteins, maintaining their native conformation, and enhancing their immunogenicity. By promoting protein-protein interactions essential for antigen presentation by Rock KL, et al. [5], molecular glues facilitate robust immune responses against viral pathogens.

Viral Vector Vaccines

Viral vector vaccines employ harmless viruses as carriers to deliver antigen-encoding genetic material into host cells. While viral vectors offer advantages such as efficient antigen delivery and immune stimulation, their stability and immunogenicity can be further optimized with molecular glues. Stabilizing viral vectors and enhancing their interaction with host cells can augment antigen expression levels and improve vaccine efficacy.

Nucleic Acid-Based Vaccines

Nucleic acid-based vaccines, including DNA and RNA vaccines, represent another promising approach for eliciting immune responses against infectious diseases. Molecular glues can enhance the stability and delivery efficiency of nucleic acid vaccines, ensuring optimal antigen expression and immune stimulation. Furthermore, Tables 1 & 2 molecular glues can modulate innate immune responses, augmenting the adaptive immune response elicited by nucleic acid vaccines by Pardi N, et al. [6].

Vaccine Technology	Description	Role of Molecular Glues
mRNA Vaccines	Utilize mRNA to encode viral antigens, eliciting an immune response.	Stabilize lipid nanoparticles (LNPs) and mRNA molecules, enhancing stability and delivery efficiency.
Protein Subunit Vaccines	Use isolated viral proteins to stimulate immune responses.	Stabilize proteins, maintain native conformation, and enhance immunogenicity by promoting antigen-presenting complexes.
Viral Vector Vaccines	Employ harmless viruses to deliver antigen-encoding genetic material into host cells.	Stabilize viral vectors and enhance their interaction with host cells to improve antigen expression and vaccine efficacy.
Nucleic Acid-Based Vaccines	Include DNA and RNA vaccines to elicit immune responses against pathogens.	Enhance stability and delivery of nucleic acids, and modulate innate immune responses to augment adaptive immunity.

Table 1: Overview of Vaccine Technologies and the Role of Molecular Glues.

Molecular Glue	Target Protein	Mechanism of Action	Clinical Status
Lenalidomide	Ikaros and Aiolos (via CRBN)	Induces ubiquitination and degradation of transcription factors	Approved for multiple myeloma
ARV-110	Androgen Receptor (AR)	PROTAC-mediated degradation of AR	Phase II clinical trials for prostate cancer
ARV-471	Estrogen Receptor (ER)	PROTAC-mediated degradation of ER	Phase I clinical trials for breast cancer
Venetoclax	BCL-2	Inhibits BCL-2, promoting apoptosis in cancer cells	Approved for chronic lymphocytic leukemia (CLL)
SMARCA2/4 Degraders	SMARCA2/4	Selective degradation of chromatin remodeling complexes	Preclinical development
PROTACs	Various oncogenic proteins	Bifunctional molecules inducing proximity between target and E3 ligase	Multiple in clinical and preclinical stages

Table 2: Molecular Glues in Cancer Therapy.

Molecular Glues in Vaccine Formulation: Mechanisms and Applications

Building upon the foundational understanding of molecular glues and their transformative potential in various therapeutic domains, the subsequent sections of this review delve deeper into the specific applications of molecular glues in vaccine formulation, cancer therapy, and cardiovascular disease (CVD) treatment. The first focal point is the exploration of molecular glues in vaccine formulation, where the intricate mechanisms of action are meticulously examined. Molecular glues function by stabilizing protein-protein interactions (PPIs), thereby enhancing the stability, immunogenicity, and delivery efficiency of vaccine components. This stabilization is crucial for maintaining the integrity and functionality of vaccine antigens, which are essential for eliciting a robust and sustained immune response. By promoting the formation of antigen-presenting complexes, molecular glues facilitate the efficient display of antigens to immune cells, thereby potentiating immune responses against viral pathogens. Additionally, molecular glues play a pivotal role in modulating immune signaling pathways, further augmenting the vaccine-induced immunity. These mechanisms collectively contribute to the increased efficacy and durability of vaccines, ensuring that they can provide long-lasting protection against infectious diseases.

The applications of molecular glues in vaccine development are multifaceted, offering numerous benefits that address some of the most pressing challenges in modern vaccine technology. One of the primary advantages is the increased stability of vaccine components, which is particularly important for vaccines that require stringent storage conditions, such as mRNA vaccines. By stabilizing lipid nanoparticles (LNPs) that encapsulate mRNA, molecular glues enhance the delivery efficiency of these vaccines, ensuring that the mRNA remains intact and functional until it reaches the target cells. This not only improves the overall effectiveness of the vaccine but also reduces the need for ultra-cold storage, thereby facilitating wider distribution and accessibility, especially in low-resource settings. Moreover, molecular glues enhance the immunogenicity of vaccines by maintaining the native conformation of viral proteins, which is critical for the proper recognition and response by the immune system. This enhanced immunogenicity translates to stronger and more consistent immune responses, providing more reliable protection against viral infections.

Furthermore, the integration of molecular glues in vaccine development offers adaptability to emerging viral variants, a crucial attribute in the face of rapidly mutating pathogens. As new variants of viruses emerge, the ability to swiftly adjust and optimize vaccine formulations is essential for maintaining their effectiveness. Molecular glues enable these rapid adjustments by stabilizing and enhancing the delivery of updated vaccine components, ensuring that vaccines remain effective against new strains. This adaptability is particularly significant in the context of global health crises, where the timely development and deployment of effective vaccines can have a profound impact on controlling disease spread and reducing mortality rates.

In addition to the extensive discussion on molecular glues in vaccine formulation, the review also encompasses their application in cardiovascular disease therapy, presented comprehensively in Table 3. This table provides an overview of various molecular glues targeting key proteins involved in cardiovascular pathologies, highlighting their mechanisms of action, therapeutic applications, and current clinical statuses. For instance, PCSK9 inhibitors represent a significant advancement in the management of hypercholesterolemia and atherosclerosis. By enhancing the degradation of PCSK9, these molecular glues increase the levels of low-density lipoprotein (LDL) receptors, thereby reducing LDL cholesterol levels and mitigating the risk of plaque formation in arterial walls. This targeted approach not only improves lipid metabolism but also offers a novel strategy for preventing cardiovascular events associated with elevated cholesterol levels.

Calcium signaling modulators, another critical category of molecular glues, target proteins involved in calcium homeostasis, which is fundamental for maintaining normal cardiac rhythm and contractility. By stabilizing interactions that promote proper calcium signaling, these molecular glues offer potential treatments for cardiac arrhythmias and heart failure, conditions that stem from disrupted calcium dynamics. The stabilization of these interactions ensures that calcium ions are appropriately regulated within cardiac cells, thereby improving myocardial function and reducing the incidence of arrhythmias, which are significant contributors to cardiovascular morbidity and mortality.

Lipid metabolism regulators, as detailed in Table 3, focus on proteins that govern lipid processing and storage within the body. Molecular glues designed to degrade pro-atherogenic factors or stabilize anti-atherogenic proteins can effectively reduce lipid accumulation in arterial walls, thereby preventing the progression of atherosclerosis. This targeted degradation approach not only addresses the underlying molecular mechanisms driving lipid accumulation but also offers a preventive strategy against the development of more severe cardiovascular conditions such as heart attacks and strokes.

The therapeutic applications of molecular glues extend beyond stabilization and degradation of proteins; they also encompass modulation of complex metabolic pathways that are dysregulated in diseases. For instance, by targeting specific enzymes or receptors involved in lipid metabolism, molecular glues can alter the metabolic fluxes, leading to improved lipid profiles and reduced cardiovascular risk factors. The clinical status of these molecular glues varies, with some, like PCSK9 inhibitors, already approved and in widespread use, while others are in preclinical or clinical trial phases, underscoring the ongoing research and development efforts aimed at expanding the therapeutic repertoire of molecular glues.

In summary, the upcoming sections of this review provide a detailed examination of how molecular glues enhance vaccine formulation through mechanisms that stabilize and improve the delivery and immune response of vaccine components. Additionally, the inclusion of Table 3 offers a comprehensive overview of the role of molecular glues in cardiovascular disease therapy, detailing their target proteins, mechanisms of action, therapeutic applications, and clinical statuses. This multifaceted exploration underscores the versatility and transformative potential of molecular glues in addressing some of the most critical health challenges of our time, highlighting their role in advancing precision medicine and improving patient outcomes across a spectrum of diseases. As the field of molecular glues continues to evolve, their integration into vaccine technologies and cardiovascular disease treatments exemplifies the innovative strides being made in drug development, promising a future where highly specific and effective therapeutic interventions are not only possible but are becoming a reality.

Mechanisms of Action

Molecular glues function by stabilizing protein-protein interactions, thereby enhancing the stability, immunogenicity, and delivery efficiency of vaccine components. By promoting the formation of antigen-presenting complexes from Smith MR, et al. [7] and Hsieh CL, et al. [8] and modulating immune signaling pathways by Pardi N, et al. [6] and Pallesen J, et al. [9] molecular glues potentiate immune responses against viral pathogens. Additionally, molecular glues can optimize the formulation of vaccine adjuvants from Hagan DT, et al. [10] and Guy B, et al. [11], further augmenting vaccine-induced immunity.

Applications in Vaccine Development

The integration of molecular glues in vaccine development offers numerous benefits, including increased stability, enhanced immunogenicity, and adaptability to emerging viral variants from Korber B, et al. [12]; Tegally H, et al. [13] and Wang C, et al. [14]. By stabilizing vaccine components and improving antigen presentation, molecular glues can enhance the efficacy and durability of vaccine-induced immunity. Moreover, the rapid response capabilities of molecular glues enable timely adjustments to vaccine formulations, ensuring continued protection against evolving viral threats.

Molecular Glue	Target Protein	Mechanism of Action	Therapeutic Application	Clinical Status
PCSK9 Inhibitors	PCSK9	Enhance degradation of PCSK9, increasing LDL receptor levels	Management of hypercholesterolemia and atherosclerosis	Approved (e.g., Alirocumab)
Calcium Signaling Modulators	Proteins involved in calcium homeostasis	Stabilize interactions to promote normal cardiac rhythm	Treatment of cardiac arrhythmias and heart failure	Preclinical and clinical trials underway
Lipid Metabolism Regulators	Proteins involved in lipid metabolism	Degrade pro-atherogenic factors or stabilize anti-atherogenic proteins	Reduction of plaque formation in arteries	Research and development phase

Table 3: Molecular Glues in Cardiovascular Disease Therapy.

Case Studies in Vaccine Development

COVID-19 Vaccines

The Pfizer-BioNTech and Moderna mRNA vaccines have demonstrated the critical role of innovative technologies in rapid vaccine development by McMahon M, et al. [15]. Molecular glues have the potential to further enhance these vaccines by stabilizing the mRNA-LNP complexes, improving delivery to cells, and increasing the efficiency of antigen presentation.

Influenza Vaccines

Nucleic acid-based influenza vaccines can benefit from molecular glues that stabilize the nucleic acids and enhance their delivery to target cells. This could lead to more effective vaccines that provide broader and longer-lasting protection against influenza viruses.

Molecular Glues in Cancer Drug Development: Targeted Therapies for Precision Medicine

Targeting Protein-Protein Interactions in Cancer

Protein-protein interactions (PPIs) are critical to various cellular processes, including those that drive cancer progression, such as signal transduction, gene expression, and cell cycle regulation. Aberrant PPIs can lead to uncontrolled cell growth, evasion of apoptosis, angiogenesis, and metastasis. Targeting these interactions offers a promising therapeutic strategy to inhibit the oncogenic pathways that cancer cells rely on Fisher SL, et al. [16] and Zhang Y, et al. [17].

Enhancing Drug Target Engagement

One significant advantage of molecular glues is their ability to enhance drug target engagement. Traditional small molecule inhibitors must fit precisely into a binding site, which can be difficult to achieve with proteins involved in PPIs. Molecular glues, however, act as intermediaries, facilitating the interaction between two proteins, thus expanding the range of druggable targets.

For example, immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide, used in the treatment of multiple myeloma, function as molecular glues. These drugs bind to cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase complex, and recruit transcription factors Ikaros and Aiolos, leading to their ubiquitination and subsequent proteasomal degradation [18-20]. This degradation disrupts cancer cell survival pathways and induces cytotoxicity in multiple myeloma cells.

Advancing Precision Medicine with Molecular Glues

Precision medicine aims to tailor treatments based on the individual genetic and molecular profiles of patients. Molecular glues offer a unique opportunity to design therapies that specifically target the molecular abnormalities driving a patient's cancer. By precisely modulating PPIs, molecular glues can achieve selective inhibition or degradation of oncogenic proteins.

Recent advances in high-throughput screening and computational modeling have facilitated the discovery of novel molecular glues. These technologies can identify compounds that induce or stabilize specific PPIs, enabling the development of targeted therapies for various cancers. For example, proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that act as molecular glues to bring an E3 ubiquitin ligase into proximity with a target protein, leading to its ubiquitination and degradation [21,22]. This strategy has shown promise in preclinical models for targeting proteins such as the androgen receptor (AR) in prostate cancer and estrogen receptor (ER) in breast cancer [23,24].

Molecular Glues in Clinical Development

Several molecular glue-based therapies are currently undergoing clinical trials, demonstrating their potential to transform cancer treatment. For instance, ARV-110, a PROTAC targeting the androgen receptor, has shown activity in patients with metastatic castration-resistant prostate cancer who have progressed on standard therapies Neklesa T, et al. [23]. Similarly, ARV-471, a PROTAC targeting the estrogen receptor, is being evaluated in patients with ER-positive breast cancer [24].

Additionally, molecular glues targeting the BCL-2 family of proteins, which regulate apoptosis, are being developed to induce selective degradation of anti-apoptotic proteins, thereby promoting cancer cell death. Venetoclax, a BCL-2 inhibitor, has shown remarkable efficacy in chronic lymphocytic leukemia and acute myeloid leukemia, and ongoing research is exploring the use of molecular glues to enhance its therapeutic effects [25].

Challenges and Future Directions

In the dynamic landscape of biomedical research, molecular glues have emerged as pivotal actors in advancing vaccine development and cancer therapeutics, showcasing their versatility and profound impact across diverse medical domains. Case studies in vaccine development highlight the critical role that molecular glues play in enhancing the efficacy and adaptability of vaccines, particularly exemplified by the rapid development and deployment of COVID-19 vaccines. The Pfizer-BioNTech and Moderna mRNA vaccines stand as landmark achievements, demonstrating the potential of innovative technologies to respond swiftly to global health crises by McMahon M, et al. [16]. These vaccines have not only underscored the importance of molecular glues in stabilizing mRNA-LNP (lipid nanoparticle) complexes but also in improving the delivery mechanisms to target cells, thereby increasing the efficiency of antigen presentation. By maintaining the integrity of mRNA molecules and ensuring their effective translation into viral antigens, molecular glues enhance the stability and functionality of mRNA vaccines, making them more resilient to degradation and improving their overall immunogenicity. Furthermore, influenza vaccines offer another compelling example of the application of molecular glues. Nucleic acid-based influenza vaccines can greatly benefit from molecular glues that stabilize the nucleic acids and enhance their delivery to target cells, potentially leading to more effective vaccines that provide broader and longer-lasting protection against various influenza strains.

This stabilization not only improves the shelf-life and storage conditions of vaccines but also ensures consistent and robust immune responses, thereby addressing the perennial challenge of antigenic drift and shift in influenza viruses.

Transitioning from vaccine development to oncology, the role of molecular glues in cancer drug development represents a significant advancement in therapeutic strategies aimed at precision medicine. Targeting protein-protein interactions (PPIs) is fundamental to disrupting the cellular processes that drive cancer progression, including signal transduction, gene expression, and cell cycle regulation by Fisher SL, et al. [16] and Zhang Y, et al. [17]. Aberrant PPIs can lead to uncontrolled cell growth, evasion of apoptosis, angiogenesis, and metastasis, making them attractive targets for therapeutic intervention. Molecular glues enhance drug target engagement by acting as intermediaries that facilitate the interaction between two proteins, thereby expanding the range of druggable targets beyond those accessible by traditional small molecule inhibitors. For instance, immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide function as molecular glues by binding to cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase complex. This binding recruits transcription factors Ikaros and Aiolos, leading to their ubiquitination and subsequent proteasomal degradation [19-21]. This targeted degradation disrupts cancer cell survival pathways and induces cytotoxicity in multiple myeloma cells, illustrating the potent therapeutic effects of molecular glues in oncology.

Advancing precision medicine, molecular glues offer the unique ability to design therapies that specifically target the molecular abnormalities unique to each patient's cancer. By precisely modulating PPIs, molecular glues achieve selective inhibition or degradation of oncogenic proteins, thereby minimizing off-target effects and enhancing therapeutic efficacy. Recent advances in high-throughput screening and computational modeling have significantly facilitated the discovery of novel molecular glues. These technologies enable the identification of compounds that can induce or stabilize specific PPIs, paving the way for the development of targeted therapies for a variety of cancers. A notable example of this innovation is the development of proteolysis-targeting chimeras (PROTACs), which are bifunctional molecules that act as molecular glues to bring an E3 ubiquitin ligase into proximity with a target protein, leading to its ubiquitination and degradation [21,22]. PROTACs have shown remarkable promise in preclinical models, particularly in targeting proteins such as the androgen receptor (AR) in prostate cancer and the estrogen receptor (ER) in breast cancer [23,24]. These successes underscore the potential of molecular glues to overcome significant challenges in cancer therapy, including drug resistance and the need for highly specific interventions.

Several molecular glue-based therapies are currently in various stages of clinical development, highlighting their potential to transform cancer treatment paradigms. For instance, ARV-110, a PROTAC targeting the androgen receptor, has demonstrated notable activity in patients with metastatic castration-resistant prostate cancer who have progressed on standard therapies Neklesa T, et al. [23]. Similarly, ARV-471, a PROTAC targeting the estrogen receptor, is undergoing evaluation in clinical trials for patients with ER-positive breast cancer [(Snyder et al., 2020)]. Additionally, molecular glues targeting the BCL-2 family of proteins, which are key regulators of apoptosis, are being developed to induce the selective degradation of anti-apoptotic proteins, thereby promoting cancer cell death. Venetoclax, a BCL-2 inhibitor, has already shown remarkable efficacy in treating chronic lymphocytic leukemia and acute myeloid leukemia, and on-going research is exploring the use of molecular glues to further enhance its therapeutic effects [25]. These developments illustrate the versatile applications of molecular glues in targeting various oncogenic pathways, thereby offering new hope for patients with resistant and refractory cancers.

Despite the promising potential of molecular glues, several challenges must be addressed to fully harness their therapeutic capabilities. One of the primary challenges lies in identifying suitable targets and designing effective molecular glues with high specificity and selectivity to minimize off-target effects and ensure therapeutic efficacy. Additionally, a comprehensive understanding of the pharmacokinetics and pharmacodynamics of molecular glues is essential for optimizing their clinical application. Factors such as stability, solubility, and bioavailability must be thoroughly evaluated to ensure that these compounds are effective in vivo. Moreover, the complex nature of PPIs necessitates a deep understanding of the underlying biology to design molecular glues that can reliably and predictably modulate specific protein interactions.

Future research directions in the field of molecular glues are poised to address these challenges through the integration of innovative screening methods, advanced computational approaches, and a deeper exploration of the mechanistic underpinnings of PPIs. Expanding the repertoire of molecular glues will involve the development of next-generation compounds with enhanced specificity, broader target ranges, and improved drug-like properties. Additionally, elucidating the detailed mechanisms of action of existing molecular glues will provide valuable insights that can guide the design of more effective and safer therapeutic agents. The continuous evolution of molecular glue technology, coupled with advancements in precision medicine, is expected to lead to the development of highly personalized treatments that offer superior efficacy and safety profiles, ultimately improving patient outcomes and advancing the fields of oncology and immunology. As research progresses, the integration of molecular glues into clinical practice will likely play a crucial role in addressing some of the most intractable health challenges, paving the way for a new era of targeted and effective therapeutic interventions.

Despite the promising potential of molecular glues, several challenges remain. One primary challenge is identifying suitable targets and designing effective molecular glues. The specificity and selectivity of these molecules are crucial to minimizing off-target effects and ensuring therapeutic efficacy.5 Moreover, understanding the pharmacokinetics and pharmacodynamics of molecular glues is essential for optimizing their clinical application. The stability, solubility, and bioavailability of these compounds must be thoroughly evaluated to ensure their effectiveness in vivo.

Future research should focus on expanding the repertoire of molecular glues through innovative screening methods and computational approaches. Additionally, elucidating the detailed mechanisms of action of these compounds will provide insights into their therapeutic potential and guide the development of next-generation molecular glues with improved efficacy and safety profiles.

Case Studies of Molecular Glues in Cancer Therapy

Cereblon Modulators

Thalidomide analogs such as lenalidomide and pomalidomide are pioneering examples of molecular glues in cancer therapy. These drugs bind to the cereblon (CRBN) E3 ubiquitin ligase complex, altering its substrate specificity to degrade Ikaros and Aiolos, transcription factors crucial for multiple myeloma cell survival [18-20]. This targeted protein degradation mechanism has revolutionized the treatment of multiple myeloma and highlights the therapeutic potential of molecular glues.

PROTACs

Proteolysis-targeting chimeras (PROTACs) are a novel class of molecular glues designed to target and degrade specific proteins. For instance, ARV-110, a PROTAC targeting the androgen receptor, has shown promise in treating metastatic castration-resistant prostate cancer. Similarly, ARV-471 targets the estrogen receptor in breast cancer, exemplifying the versatility of PROTAC technology [23,24].

SMARCA2/4 Degraders

Recent advancements have identified molecular glues that selectively degrade SMARCA2/4, components of the SWI/SNF chromatin remodeling complex, which are implicated in various cancers. These degraders exploit the differential dependencies of cancer cells on these proteins, providing a targeted therapeutic approach with reduced off-target toxicity [26].

Molecular Glues in Cardiovascular Disease Therapy: A New Frontier

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, necessitating the development of innovative therapeutic strategies. Molecular glues have the potential to target key proteins involved in cardiovascular pathology, offering novel approaches for treating conditions such as heart failure, atherosclerosis, and hypertension.

Mechanisms and Applications in Cardiovascular Therapy

Molecular glues can modulate protein-protein interactions critical for cardiovascular function and disease. For example, they can stabilize or degrade proteins involved in cardiac contractility, vascular tone, and lipid metabolism. By targeting these interactions, molecular glues can provide precise modulation of cardiovascular pathways, leading to improved therapeutic outcomes.

Targeting Cardiac Contractility

Heart failure, characterized by impaired cardiac contractility, is a major public health concern. Molecular glues can target proteins involved in calcium signaling and contractile function, enhancing cardiac output and reducing symptoms of heart failure. For instance, stabilizing interactions between cardiac troponin and other contractile proteins can improve myocardial function and prevent heart failure progression by Zhang Y, et al. [17].

Modulating Vascular Tone

Hypertension, a leading risk factor for cardiovascular diseases, results from dysregulated vascular tone. Molecular glues can target proteins that regulate smooth muscle contraction and relaxation, providing precise control over blood pressure. By stabilizing or degrading key regulators of vascular tone, molecular glues offer a novel approach to hypertension management [27].

Regulating Lipid Metabolism

Atherosclerosis, characterized by lipid accumulation in arterial walls, is a major contributor to cardiovascular morbidity and mortality. Molecular glues can target proteins involved in lipid metabolism, promoting the degradation of pro-atherogenic factors or stabilizing anti-atherogenic proteins. This targeted approach can reduce plaque formation and improve cardiovascular outcomes [28].

Case Studies in Cardiovascular Disease Therapy

Targeting PCSK9

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) receptor degradation, influencing cholesterol levels and atherosclerosis risk. Molecular glues targeting PCSK9 can enhance its degradation, increasing LDL receptor levels and reducing LDL cholesterol. This approach offers a novel strategy for managing hypercholesterolemia and preventing cardiovascular events [28].

Modulating Calcium Signaling

Cardiac arrhythmias and heart failure are often associated with dysregulated calcium signaling. Molecular glues can target proteins involved in calcium homeostasis, stabilizing interactions that promote normal cardiac rhythm and contractility. This targeted approach can improve cardiac function and reduce the burden of heart failure and arrhythmias by Zhang Y, et al. [17].

Challenges and Future Directions

The application of molecular glues in cardiovascular therapy is still in its early stages, with several challenges to overcome. Identifying suitable targets and designing specific molecular glues with minimal off-target effects is crucial for their successful application in cardiovascular diseases. Moreover, understanding the long-term effects of these therapies on cardiovascular function and overall health is essential.

Future research should focus on expanding the repertoire of molecular glues for cardiovascular targets and optimizing their pharmacokinetic and pharmacodynamic properties. Additionally, clinical trials are necessary to evaluate the safety and efficacy of these novel therapies in patients with cardiovascular diseases.

Conclusion

The advent of molecular glues has ushered in a new era in therapeutic development, offering unprecedented opportunities to target complex protein-protein interactions (PPIs) that were previously deemed "undruggable." In the realm of cancer therapy, molecular glues such as cereblon modulators exemplify the profound impact of this innovative approach. Thalidomide analogs like lenalidomide and pomalidomide have revolutionized the treatment of multiple myeloma by binding to the cereblon (CRBN) E3 ubiquitin ligase complex, thereby altering its substrate specificity to degrade crucial transcription factors Ikaros and Aiolos [18-20]. This targeted protein degradation not only disrupts cancer cell survival pathways but also minimizes adverse effects on healthy cells, enhancing the therapeutic index and patient tolerability.

Further expanding the scope of molecular glues in oncology are Proteolysis-Targeting Chimeras (PROTACs), a novel class designed to degrade specific proteins by simultaneously binding to a target protein and an E3 ubiquitin ligase. PROTACs such as ARV-110 and ARV-471 have shown remarkable promise in clinical settings, targeting the androgen receptor in metastatic castration-resistant prostate cancer and the estrogen receptor in breast cancer, respectively Neklesa T, et al. [23] and Snyder LB, et al. [24]. These bifunctional molecules exemplify the versatility of PROTAC technology, offering a potent means to eliminate oncogenic proteins that drive tumor progression. Additionally, recent advancements have introduced molecular glues that selectively degrade SMARCA2/4, key components of the SWI/SNF chromatin remodeling complex implicated in various cancers [26]. By exploiting the dependency of cancer cells on these proteins, SMARCA2/4 degraders provide a targeted therapeutic approach with reduced off-target toxicity, further showcasing the precision and efficacy of molecular glues in cancer treatment.

In the field of cardiovascular disease (CVD) therapy, molecular glues represent a new frontier with the potential to address some of the most challenging aspects of heart health. Cardiovascular diseases, including heart failure, atherosclerosis, and hypertension, remain the leading causes of morbidity and mortality worldwide, driven by intricate molecular mechanisms involving dysregulated PPIs. Molecular glues can modulate these interactions, providing precise therapeutic interventions that enhance cardiac contractility, regulate vascular tone, and improve lipid metabolism. For instance, targeting cardiac contractility involves molecular glues that stabilize interactions between cardiac troponin and other contractile proteins, thereby enhancing myocardial function and preventing heart failure progression [17]. Similarly, in the management of hypertension, molecular glues targeting proteins that regulate smooth muscle contraction and relaxation offer a novel approach to modulate vascular tone, ensuring precise control over blood pressure [27].

A notable case study in cardiovascular therapy is the targeting of proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein (LDL) receptor degradation. Molecular glues enhancing the degradation of PCSK9 can increase LDL receptor levels, thereby reducing LDL cholesterol and mitigating the risk of atherosclerosis [28]. Approved PCSK9 inhibitors, such as Alirocumab, exemplify the clinical viability of molecular glues in managing hypercholesterolemia and preventing cardiovascular events. Additionally, molecular glues that modulate calcium signaling pathways involved in cardiac arrhythmias and heart failure offer substantial promise. By stabilizing interactions that promote normal cardiac rhythm and contractility, these molecular glues can significantly improve cardiac function and reduce the burden of heart failure and arrhythmias from Zhang Y, et al. [17].

Despite the remarkable advancements, the application of molecular glues in both cancer and cardiovascular therapies is not without challenges. Identifying suitable targets and designing effective molecular glues with high specificity and selectivity remains a primary hurdle. Off-target effects can lead to unintended consequences, underscoring the need for meticulous molecular design and thorough pharmacokinetic and pharmacodynamic evaluations. Additionally, the stability, solubility, and bioavailability of molecular glues must be optimized to ensure their effectiveness in vivo. Understanding the long-term impacts of these therapies on cardiovascular and overall health is crucial to their successful clinical application [29-34].

Looking forward, the future of molecular glues is bright, with ongoing research focused on expanding their repertoire through innovative screening methods and computational approaches. High-throughput screening and advanced computational modeling are integral to identifying new molecular glues that can target a broader range of PPIs with enhanced efficacy and safety profiles. Furthermore, elucidating the detailed mechanisms of action of existing molecular glues will provide deeper insights into their therapeutic potential, guiding the development of next-generation compounds with improved properties. The integration of molecular glues into precision medicine frameworks holds significant promise, enabling highly personalized treatments tailored to individual genetic and molecular profiles. This alignment with precision medicine principles ensures that therapies are not only effective but also minimize adverse effects, thereby enhancing patient outcomes and advancing the fields of oncology, immunology, and cardiovascular medicine [35-38].

In conclusion, molecular glues represent a revolutionary approach in the development of next-generation vaccines, cancer therapeutics, and cardiovascular disease treatments. By enabling the precise targeting and modulation of critical protein-protein interactions, molecular glues offer novel therapeutic strategies characterized by high specificity and reduced side effects. The successful case studies in cancer therapy, including cereblon modulators, PROTACs, and SMARCA2/4 degraders, alongside the promising applications in cardiovascular disease therapy, highlight the versatile and transformative potential of molecular glues. As research continues to advance, the integration of molecular glues into precision medicine and vaccine technologies is poised to significantly improve patient outcomes, addressing some of the most pressing health challenges of our time. The continued exploration and development of molecular glues hold great promise for revolutionizing the landscape of therapeutic interventions, ultimately contributing to the advancement of global health and well-being [39-45].

Molecular glues represent a revolutionary approach in both vaccine development and cancer drug discovery by enabling the targeting of protein-protein interactions critical for immune responses and cancer progression. Their ability to induce selective degradation of oncogenic proteins and stabilize vaccine components offers novel therapeutic strategies with the potential for high specificity and reduced side effects. Additionally, the application of molecular glues in cardiovascular disease therapy opens new avenues for treating conditions such as heart failure, atherosclerosis, and hypertension [46-49].

As research progresses, the integration of molecular glues into precision medicine and vaccine technologies will likely lead to more effective and personalized treatments, ultimately improving patient outcomes and advancing the fields of oncology, immunology, and cardiovascular medicine. The continued exploration and development of molecular glues hold great promise for addressing some of the most pressing health challenges of our time, revolutionizing the landscape of therapeutic interventions.

References

1. Anderson EJ, Rouphael N, Widge A, Jackson L, Roberts P, et al. (2020) Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine.

2. Polack FP, Thomas SJ, Kitchin N (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine.

3. Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, et al. (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science.

4. Walls AC, Young J, Alejandra T, David V, Wall A, et al. (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell.

5. Rock KL (2016) MHC class I cross-presentation of exogenous antigens. Nature Reviews Immunology.

6. Pardi N, Krammer F (2018) Development of mRNA vaccines against influenza. Trends in Molecular Medicine.

7. Smith MR (2019) Protein-Protein Interactions: Small Molecules Matter. Journal of Medicinal Chemistry.

8. Hsieh CL, Goldsmith J, Schaub J, Kuo H, Javanmardi K, et al. (2020) Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science.

9. Pallesen J, Wrapp D, Kirchdoerfer R, Turner H, Cottrell C, et al. (2017) Immunogenicity and structures of a rationally designed perfusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences.

10. Hagan DT (2020) Recent developments in vaccine adjuvants. Current Opinion in Immunology.

11. Guy B (2001) The adjuvant activity of aluminum hydroxide: Transient activation of macrophages. Vaccine.

12. Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, et al. (2020) Tracking changes in SARS-CoV-2 Spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell.

13. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, et al. (2021) Detection of a SARS-CoV-2 variant of concern in South Africa. Nature.

14. Wang X, Tsybovsky Y, Gorman J, Rapp M, Cerutti G, et al. (2021) Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains. Cell Host & Microbe.

15. McMahon M, Crandall M, Enick P, Sobolewksi M (2021) Comparative safety and immunogenicity of RNA-based Covid-19 vaccines. JAMA.

16. Fisher SL (2018) Targeted protein degradation: A new strategy to overcome drug resistance and avoid toxicity. Current Opinion in Biotechnology.

17. Zhang Y (2020) Molecular glues: A promising strategy for cancer therapy. Trends in Cancer.

18. Ito T (2010) Identification of CRBN as a target for lenalidomide in human multiple myeloma cells. Science.

19. Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, et al. (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343: 6168.

20. Lu G, Middleton RE, Sun H, Naniong M, Christopher JO, et al. (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343: 6168.

21. Toure M, Crews CM (2016) Small-molecule PROTACs: New approaches to protein degradation. Angewandte Chemie International Edition 55(6): 1966-1973.

22. Jiang J (2020) Proteolysis targeting chimeras (PROTACs) as a novel cancer therapeutic strategy. International Journal of Molecular Sciences.

23. Neklesa T, Snyder LB, Willard RR, Vitale N, Raina K, et al. (2018) ARV-110: An androgen receptor PROTAC degrader for prostate cancer. Journal of Clinical Oncology 78(13_Supplement): 5268.

24. Snyder LB (2020) ARV-471, a PROTAC degrader of the estrogen receptor, is highly efficacious in preclinical models of breast cancer. Cancer Research.

25. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, et al. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine 19: 202-208.

26. Olson CM (2018) A SMARCA2/4-selective degrader potentiates the effects of SMARCA4 loss in cancer. Nature Cell Biology.

27. Scott JD, Pawson T (2009) Cell signaling in space and time: Where proteins come together and work together. Science.

28. Rodriguez R (2019) Targeting the PCSK9-LDL receptor interaction for the treatment of hypercholesterolemia. Nature Reviews Drug Discovery.

29. Crotty S (2004) Germinal centers and the maturation of humoral immune responses. Immunity.

30. Laidlaw BJ, Craft J, Kaech S (2016) CD4+ T cell help guides the formation of B cell memory. Nature Immunology.

31. Seder RA, Darrah P, Roederer M (2008) T-cell quality in memory and protection: Implications for vaccine design. Nature Reviews Immunology.

32. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, et al. (2021) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371: 6529.

33. Liu J (2020) Molecular glues stabilize SLX4 complex to promote DNA repair and sensitize cancer cells to chemotherapy. Nature Communications.

34. Li G (2019) Molecular glue targeting RNF114 induces degradation of non-small cell lung cancer. Cancer Cell.

35. Liao H (2020) Targeted protein degradation as a new

strategy for drug discovery. Nature Reviews Drug Discovery.

36. Pfister JJ (2018) Molecular glue degradation of CDK9 by Cereblon modulator CC-90009 promotes apoptosis in AML. Nature Chemical Biology.

37. Lu Lv, Peihao C, Longzhi C, Yamei L, Zhi Z, et al. (2021) Discovery of a molecular glue promoting CDK12-DDB1 interaction to induce Cyclin K degradation. Nature Chemical Biology.

38. Chen X (2020) Design and synthesis of PROTACs: A novel approach for cancer therapy. Medicinal Research Reviews.

39. Wang X (2020) Targeting protein degradation pathways with PROTACs: A promising approach for cancer therapy. Drug Discovery Today.

40. Li W (2018) The role of PROTACs in the degradation of oncogenic proteins and cancer therapy. Oncotarget.

41. Choudhary S (2020) Targeting cardiovascular diseases with protein degradation technologies. Frontiers in Cardiovascular Medicine.

42. Liu X (2019) Emerging applications of molecular glues in cardiovascular disease treatment. Trends in Cardiovascular Medicine.

43. Hu X (2021) Molecular glues: A new frontier in cardiovascular drug discovery. Journal of Cardiovascular Pharmacology.

44. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, et al. (2019) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. New England Journal of Medicine.

45. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, et al. (2019) Safety and efficacy of bempedoic acid to reduce LDL cholesterol. New England Journal of Medicine.

46. Kar S (2018) Molecular glues: Potential therapeutic agents for regulating cardiovascular protein interactions. Circulation Research.

47. Zhang Y (2020) Novel approaches to targeting calcium signaling in heart failure. Journal of Molecular and Cellular Cardiology.

48. Wang C (2021) Harnessing molecular glues to treat cardiovascular diseases: Current status and future perspectives. Nature Reviews Cardiology.

49. Luscher TF (2017) Molecular mechanisms of cardiovascular aging and potential therapeutic targets. Nature Reviews Cardiology.